Clinical trials: Sirolimus, completed
Coronary Artery Disease, Coronary Disease
Sirolimus-eluting vs Zotarolimus-eluting Stents for Chronic Total Coronary Occlusions
Primary intracoronary stent placement after successfully crossing chronic total coronary occlusions (CTO) decreases the high restenosis rate at long-term follow-up compared with conventional balloon angioplasty.
- Conditions
- Coronary Artery Disease, Coronary Disease, Coronary Stenosis
- Trial name
- NCT00428454
- Testing
- sirolimus-eluting stent, zotarolimus-eluting stent
- Where
- 5 sites in Belgium, Netherlands
- Volunteers
- 301 people
- Sponsor
- R&D Cardiologie
Coronary Heart Disease
Rapamycin-Eluting Stents With Different Polymer Coating to Reduce Restenosis (ISAR-TEST-3)
The purpose of this study is to evaluate the efficacy of 3 different rapamycin-eluting-stent platforms to reduce coronary artery reblockage after stent implantation
- Trial name
- NCT00350454
- Testing
- rapamycin-eluting Stent with permanent polymer, rapamycin-eluting stent with biodegradable polymer, polymer-free, rapamycin-eluting stent
- Where
- 2 sites in Germany
- Volunteers
- 605 people
- Sponsor
- Deutsches Herzzentrum Muenchen
Non Small Cell Lung Cancer
Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer
The purpose of this study is to determine whether the investigational study drug everolimus may be used to increase the effectiveness of chemotherapy treatment for patients with advanced lung cancer.
- Trial name
- NCT01700400
- Testing
- Everolimus, Pemetrexed, Carboplatin
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- Cancer Research and Biostatistics Clinical Trials Consortium
Malignant Solid Tumour
Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors
This is a dose escalation trial to evaluate twice daily dosing of the sachet formulation of BEZ235. This trial will find the maximum tolerated dose (MTD) of the sachet formulation given twice daily, as well as evaluate…
- Trial name
- NCT01343498
- Testing
- BEZ235
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- SCRI Development Innovations, LLC
Bioequivalence Study
Bioequivalence Study of NPC-12 (Sirolimus) Granules and Tablets
The purpose of this study is to evaluate the bioequivalece of NPC-12 granules in compare with NPC-12T tablets in Japanese healthy Adults
- Trial name
- NCT03765944
- Testing
- sirolimus
- Where
- Japan
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Nobelpharma
HER2/Neu Over-expressing Locally Advanced Breast Cancer, Metastatic Breast Cancer
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
This phase III, double-blind, placebo-controlled multinational study will assess the combination everolimus, vinorelbine, and trastuzumab compared to the combination vinorelbine and trastuzumab with respect to progressive-free…
- Trial name
- BOLERO-3 (NCT01007942)
- Testing
- everolimus, vinorelbine, trastuzumab
- Where
- 161 sites in United States, Argentina and 19 more
- Volunteers
- 569 people
- Sponsor
- Novartis Pharmaceuticals
Gastrointestinal Neoplasms
Phase II Study of Everolimus Combined With Octreotide LAR to Treat Advanced GI NET
The underlying hypothesis of the synergistic activity of octreotide and everolimus is based on the combination of a) a direct action of everolimus over mTOR (mammalian target of rapamycin), and b) the inhibitory effect of…
- Trial name
- EVERLAR (NCT01567488)
- Testing
- Everolimus, octreotide LAR
- Where
- Spain
- Volunteers
- 43 people
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
Brain Tumor, Recurrent, Glioblastoma
Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas
The purpose of this study is to test the effectiveness of a drug called temsirolimus in combination with a drug called perifosine in treating brain tumors that have continued to grow after previous treatment.
- Conditions
- Brain Tumor, Recurrent, Glioblastoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
- Trial name
- NCT02238496
- Testing
- Cytoreductive surgery, Perifosine, Temsirolimus
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Andrew B Lassman, MD
Renal Transplantation
This is a 2-year Follow-up Study to Evaluate the Long-term Effects in Patients Who Completed the Study CRAD001A2307.
This extension study is designed to provide long-term safety and efficacy data beyond 12 months up to Month 36.
- Trial name
- NCT00531440
- Testing
- Everolimus (RAD001)
- Where
- Switzerland
- Volunteers
- 256 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Gastric Cancer
Low-dose RAD001(Everolimus) Plus Cisplatin-HDFL Chemotherapy for the First-line Treatment of Advanced Gastric Cancer
The primary end-point of this study is to evaluate the objective response rates, and the secondary end-points are overall survival, progression-free survival and safety profile of low-dose RAD001 (everolimus) plus cisplatin and…
- Trial name
- NCT00632268
- Testing
- RAD001; Cisplatin; 5-FU; Leucovorin
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- National Taiwan University Hospital
Recurrent Childhood Ependymoma
Everolimus for Children With Recurrent or Progressive Ependymoma
The purpose of this study is to evaluate the anti-tumor activity of Everolimus among children with recurrent or progressive ependymoma. Recurrent or progressive ependymoma is incurable and has very limited treatment options.
- Trial name
- NCT02155920
- Testing
- Everolimus
- Where
- 4 sites in United States
- Volunteers
- 11 people
- Sponsor
- University of Texas Southwestern Medical Center
PRETEXT I Hepatoblastoma, PRETEXT II Hepatoblastoma
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer
This phase III trial studies the side effects and how well risk-based therapy works in treating younger patients with newly diagnosed liver cancer.
- Conditions
- PRETEXT I Hepatoblastoma, PRETEXT II Hepatoblastoma, PRETEXT III Hepatoblastoma, PRETEXT IV Hepatoblastoma
- Trial name
- NCT00980460
- Testing
- Cisplatin, Dexrazoxane, Doxorubicin Hydrochloride
- Where
- 209 sites in United States, Australia and 4 more
- Volunteers
- 236 people
- Sponsor
- National Cancer Institute (NCI)
Cholangiocarcinoma of the Gallbladder, Localized Gallbladder Cancer
Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy
This randomized phase I trial is studying the side effects and best dose of everolimus, gemcitabine hydrochloride, and cisplatin in treating patients with unresectable solid tumors refractory to standard therapy.
- Conditions
- Cholangiocarcinoma of the Gallbladder, Localized Gallbladder Cancer, Unresectable Gallbladder Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00949949
- Testing
- everolimus, gemcitabine hydrochloride, cisplatin
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- Mayo Clinic
Renal Cell Carcinoma
Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma
This is a pilot, single-center, single-arm study where 20 patients with metastatic or unresectable clear cell renal cell carcinoma will receive same sequential treatment strategy (Cabozantinib for 12 weeks, then proceed with…
- Trial name
- NCT05188118
- Testing
- Cabozantinib, Ipilimumab, Nivolumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
In-stent Restenosis
Diffuse Type In-Stent Restenosis After Drug-Eluting Stent
To evaluate the best therapeutic option for the treatment of diffuse type post-drug-eluting stent restenosis.
- Trial name
- DES-ISR (NCT00485030)
- Testing
- Cypher, Xience-V
- Where
- 15 sites in South Korea
- Volunteers
- 60 people
- Sponsor
- Seung-Jung Park
Tuberous Sclerosis, Subependymal Giant Cell Astrocytoma
Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1)
This study evaluated the efficacy and safety of Everolimus in treating patients with Subependymal Giant Cell Astrocytomas associated with Tuberous Sclerosis Complex.
- Trial name
- EXIST-1 (NCT00789828)
- Testing
- Everolimus
- Where
- 24 sites in United States, Australia and 8 more
- Volunteers
- 117 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Transplantation
Regimen Optimization Study
Patients who undergo a kidney transplant require prolonged therapy with drugs that suppress the immune system (called immunosuppressive regimens) to stop the immune system from attacking the transplanted kidney in order to limit…
- Trial name
- NCT02137239
- Testing
- Thymoglobulin, Belatacept, mycophenolate mofetil(MMF)
- Where
- 20 sites in United States, Argentina
- Volunteers
- 58 people
- Sponsor
- Bristol-Myers Squibb
Coronary Heart Disease
Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization
Context: Sirolimus-eluting stents and paclitaxel-eluting stents, as compared with bare-metal stents, reduce the risk of restenosis.
- Trial name
- NCT00297661
- Testing
- Sirolimus-eluting stent, Paclitaxel-eluting stent
- Where
- Switzerland
- Volunteers
- 1,012 people
- Sponsor
- University of Bern
Systemic Lupus Erythematosus
Effectiveness of Belimumab Treatment in a Subpopulation of Systemic Lupus Erythematosus (SLE) Patients: a Pooled Analysis of BLISS-52 and BLISS-76
This pooled analysis will assess data from the Phase 3 belimumab registration studies BLISS-52 (aka BEL110752) and BLISS-76 (aka BEL110751). The analysis was pre-planned and agreed prior to the unblinding of either study.
- Trial name
- NCT01914770
- Testing
- Belimumab 1 mg/kg, Belimumab 10 mg/kg
- Volunteers
- 1,016 people
- Sponsor
- GlaxoSmithKline
Diabetic Macular Edema
Dose Ranging Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Diabetic Macular Edema
The purpose of this study is to determine the safety and efficacy of an ocular sirolimus (rapamycin) formulation at various doses in patients with diabetic macular edema.
- Trial name
- NCT00656643
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 131 people
- Sponsor
- Santen Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.